Unique ID issued by UMIN | UMIN000019093 |
---|---|
Receipt number | R000022077 |
Scientific Title | Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14) |
Date of disclosure of the study information | 2015/10/01 |
Last modified on | 2018/05/07 08:42:51 |
Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14)
Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14)
Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14)
Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14)
Japan |
Hodgkin's lymphoma
Hematology and clinical oncology | Pediatrics |
Malignancy
NO
In targeting cases of Hodgkin's lymphoma (HL) in children under age 20, we confirm whether we can omit radiation therapy for FDG-PET negative cases after 2 courses of multi-drug chemotherapy. By determining remission using PET examinations with both high sensitivity and high specificity, the goal is to detect the cases that truly require radiation therapy, and for other cases carry out treatment without radiation therapy, in order to maintain a high survival rate while ensuring safety.
Safety,Efficacy
Exploratory
Phase II
5-year event-free survival
5-year overall survival
ratio of complete remission
ratio of interim-PET negative
ratio of acute and late side effect
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine | Device,equipment |
Omit radiation therapy for FDG-PET negative cases after 2 courses of multi-drug chemotherapy
0 | years-old | <= |
20 | years-old | > |
Male and Female
(1) diagnosis of Hodgkin's lymphoma
(2) age under 20 year old at diagnosis
(3) registration at JPLSG CHM-14 study
(4) written informed consent obtained from patient or guardians.
(1) Cases where impaired liver, kidney and cardiac functions compromise experimental treatment
(2) Patients who have been treated with anticancer drugs or radiation therapy
(3) Presence of CNS degenerative lesion
(4) Associated intracranial hemorrhage which hinders execution of treatment process
(5) Associated infection which is difficult to control
(6) Pregnant or possibility of pregnancy
(7) Women who are breastfeeding
(8) Past history of malignant neoplasm or multiple primary neoplasms
(9) History of congenital or acquired immune deficiency syndrome
(10) Any other reasons that the attending physician has deemed unsuitable
50
1st name | |
Middle name | |
Last name | Yuhki Koga |
Graduate School of Medical Sciences Kyushu University
Department of Pediatrics
3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582
092-642-5093
yuuki-k@pediatr.med.kyushu-u.ac.jp
1st name | |
Middle name | |
Last name | Yuhki Koga |
Graduate School of Medical Sciences Kyushu University
Department of Pediatrics
3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582
092-642-5093
http://jplsg.jp/index.htm
yuuki-k@pediatr.med.kyushu-u.ac.jp
Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)
Grant for clinical cancer research from the Ministry of Health, Labour and Welfare, Japan
Japan
Grant from the National Center for Child Health and Development
NO
2015 | Year | 10 | Month | 01 | Day |
http://jplsg.jp/index.htm
Unpublished
Enrolling by invitation
2015 | Year | 08 | Month | 21 | Day |
2015 | Year | 10 | Month | 01 | Day |
2015 | Year | 09 | Month | 23 | Day |
2018 | Year | 05 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022077